Bridget E. Bunner

Array ( [id] => 11040179 [patent_doc_number] => 20160237135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-18 [patent_title] => 'INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/024787 [patent_app_country] => US [patent_app_date] => 2014-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 15521 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15024787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321286 [patent_doc_number] => 10781242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Interleukin-2 fusion proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 15/024792 [patent_app_country] => US [patent_app_date] => 2014-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16920 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15024792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11011376 [patent_doc_number] => 20160208329 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-21 [patent_title] => 'SYSTEMS, DEVICES AND METHODS FOR ANTI-TL1A THERAPY' [patent_app_type] => utility [patent_app_number] => 14/915544 [patent_app_country] => US [patent_app_date] => 2014-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12596 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14915544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16276849 [patent_doc_number] => 10759863 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Modulation of gd T cells [patent_app_type] => utility [patent_app_number] => 14/916986 [patent_app_country] => US [patent_app_date] => 2014-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 32 [patent_no_of_words] => 11378 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14916986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9864662 [patent_doc_number] => 20150044681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'METHOD TO PREDICT THE PATTERN OF LOCOMOTION IN HORSES' [patent_app_type] => utility [patent_app_number] => 14/467594 [patent_app_country] => US [patent_app_date] => 2014-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9062 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14467594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9908987 [patent_doc_number] => 20150064189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent' [patent_app_type] => utility [patent_app_number] => 14/457968 [patent_app_country] => US [patent_app_date] => 2014-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15029 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14457968 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10938903 [patent_doc_number] => 20140341924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/453461 [patent_app_country] => US [patent_app_date] => 2014-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13455 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14453461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10938904 [patent_doc_number] => 20140341925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/453490 [patent_app_country] => US [patent_app_date] => 2014-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13456 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14453490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11082271 [patent_doc_number] => 20160279236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'USE OF RAPAMYCIN AS VACCINE ADJUVANT AND PREPARATION METHOD THEREFOR' [patent_app_type] => utility [patent_app_number] => 14/907769 [patent_app_country] => US [patent_app_date] => 2014-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6094 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14907769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9812016 [patent_doc_number] => 20150023961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-22 [patent_title] => 'METHODS OF MODULATING IMMUNOLOGICAL RESPONSES BY ADMINISTERING TRUNCATED BAFF RECEPTORS' [patent_app_type] => utility [patent_app_number] => 14/444139 [patent_app_country] => US [patent_app_date] => 2014-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 11611 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14444139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10815327 [patent_doc_number] => 20160161487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'CONTROL OF UTERINE CONTRACTIONS' [patent_app_type] => utility [patent_app_number] => 14/905875 [patent_app_country] => US [patent_app_date] => 2014-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 14884 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14905875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11018093 [patent_doc_number] => 20160215046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY' [patent_app_type] => utility [patent_app_number] => 14/900024 [patent_app_country] => US [patent_app_date] => 2014-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 10187 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14900024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10974149 [patent_doc_number] => 20140377184 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'Methods and Compositions Related to Targeting Tumors and Wounds' [patent_app_type] => utility [patent_app_number] => 14/331048 [patent_app_country] => US [patent_app_date] => 2014-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24233 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14331048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11100895 [patent_doc_number] => 20160297865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'METHODS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/902966 [patent_app_country] => US [patent_app_date] => 2014-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18687 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14902966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14551259 [patent_doc_number] => 10344072 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Soluble CD33 for treating myelodysplastic syndromes (MDS) [patent_app_type] => utility [patent_app_number] => 14/902719 [patent_app_country] => US [patent_app_date] => 2014-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 79 [patent_no_of_words] => 23098 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14902719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10887749 [patent_doc_number] => 08911741 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-16 [patent_title] => 'Formulation of human antibodies for treating TNF-alpha associated disorders' [patent_app_type] => utility [patent_app_number] => 14/322581 [patent_app_country] => US [patent_app_date] => 2014-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13423 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14322581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10911763 [patent_doc_number] => 20140314781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/322565 [patent_app_country] => US [patent_app_date] => 2014-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13605 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14322565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10706869 [patent_doc_number] => 20160053016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/308371 [patent_app_country] => US [patent_app_date] => 2014-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 35854 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14308371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219467 [patent_doc_number] => 20150104461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'ANTI-NOTCH2 NRR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/298488 [patent_app_country] => US [patent_app_date] => 2014-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 51120 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14298488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219467 [patent_doc_number] => 20150104461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'ANTI-NOTCH2 NRR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/298488 [patent_app_country] => US [patent_app_date] => 2014-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 51120 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14298488 [rel_patent_id] =>[rel_patent_doc_number] =>)